These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12052669)

  • 21. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
    Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ
    Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High incidence of mild hyponatraemia in females using ecstasy at a rave party.
    van Dijken GD; Blom RE; Hené RJ; Boer WH; NIGRAM Consortium
    Nephrol Dial Transplant; 2013 Sep; 28(9):2277-83. PubMed ID: 23476039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotoxicity of MDMA: Main effects and mechanisms.
    Costa G; Gołembiowska K
    Exp Neurol; 2022 Jan; 347():113894. PubMed ID: 34655576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurological and cognitive alterations induced by MDMA in humans.
    Montgomery C; Roberts CA
    Exp Neurol; 2022 Jan; 347():113888. PubMed ID: 34624331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of MDMA (Ecstasy) on the human central nervous system revealed by visual evoked potentials.
    Casco C; Forcella M; Beretta G; Grieco A; Campana G
    Addict Biol; 2005 Jun; 10(2):187-95. PubMed ID: 16191672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney.
    Campbell GA; Rosner MH
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1852-60. PubMed ID: 18684895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in prefrontal blood oxygenation during an acute multitasking stressor in ecstasy polydrug users.
    Roberts CA; Wetherell MA; Fisk JE; Montgomery C
    Psychol Med; 2015 Jan; 45(2):395-406. PubMed ID: 25066866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users.
    Stuerenburg HJ; Petersen K; Bäumer T; Rosenkranz M; Buhmann C; Thomasius R
    Neuro Endocrinol Lett; 2002 Jun; 23(3):259-61. PubMed ID: 12080289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular autonomic dysregulation in users of MDMA ("Ecstasy").
    Brody S; Krause C; Veit R; Rau H
    Psychopharmacology (Berl); 1998 Apr; 136(4):390-3. PubMed ID: 9600585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hippocampal remodelling after MDMA neurotoxicity: a single case study.
    Nifosì F; Martinuzzi A; Toffanin T; Costanzo R; Vestri A; Battaglia M; Bertagnoni GE; Lupi A; Amistà P; Carollo C; Perini G
    World J Biol Psychiatry; 2009; 10(4 Pt 3):961-8. PubMed ID: 18609419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users.
    Daumann J; Fischermann T; Heekeren K; Henke K; Thron A; Gouzoulis-Mayfrank E
    Psychopharmacology (Berl); 2005 Aug; 180(4):607-11. PubMed ID: 15372137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users.
    Erritzoe D; Frokjaer VG; Holst KK; Christoffersen M; Johansen SS; Svarer C; Madsen J; Rasmussen PM; Ramsøy T; Jernigan TL; Knudsen GM
    Arch Gen Psychiatry; 2011 Jun; 68(6):562-76. PubMed ID: 21646575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain serotonin synthesis in MDMA (ecstasy) polydrug users: an alpha-[(11) C]methyl-l-tryptophan study.
    Booij L; Soucy JP; Young SN; Regoli M; Gravel P; Diksic M; Leyton M; Pihl RO; Benkelfat C
    J Neurochem; 2014 Dec; 131(5):634-44. PubMed ID: 25041501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Is the anxiety about Ecstasy justified?].
    Möller-Nehring E; Luderer HJ
    Fortschr Med; 1997 Mar; 115(7):28, 31-2, 34. PubMed ID: 9173018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users.
    McCann UD; Eligulashvili V; Mertl M; Murphy DL; Ricaurte GA
    Psychopharmacology (Berl); 1999 Nov; 147(1):56-65. PubMed ID: 10591869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ecstasy-associated pneumomediastinum.
    Marasco SF; Lim HK
    Ann R Coll Surg Engl; 2007 May; 89(4):389-93. PubMed ID: 17535617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.
    Reneman L; de Win MM; van den Brink W; Booij J; den Heeten GJ
    J Psychopharmacol; 2006 Mar; 20(2):164-75. PubMed ID: 16510475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.
    Parrott AC; Buchanan T; Heffernan TM; Scholey A; Ling J; Rodgers J
    Psychopharmacology (Berl); 2003 Jun; 167(4):449-50. PubMed ID: 12682712
    [No Abstract]   [Full Text] [Related]  

  • 39. [Investigations on the effect of "ecstasy" on cerebral glucose metabolism: an 18-FDG PET study].
    Schreckenberger M; Gouzoulis-Mayfrank E; Sabri O; Arning C; Tuttass T; Schulz G; Kaiser HJ; Wagenknecht G; Sass H; Büll U
    Nuklearmedizin; 1998; 37(8):262-7. PubMed ID: 9868707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence.
    Dafters RI; Duffy F; O'Donnell PJ; Bouquet C
    Psychopharmacology (Berl); 1999 Jul; 145(1):82-90. PubMed ID: 10445376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.